v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2026
Sep. 30, 2025
Current Assets:    
Cash and cash equivalents $ 17,007,523 $ 4,252,290
Accounts receivable, net of allowances 686,235
Inventory 22,625,945 22,286,693
Prepaid expenses 3,011,660 1,395,490
Total Current Assets 43,331,363 27,934,473
Operating lease right-of-use asset, net 753,039 818,694
Deposits 38,062 38,062
In-process research and development, net of accumulated amortization 88,785,938 92,800,000
Goodwill 9,346,796 9,346,796
Total Other Assets 98,170,796 102,184,858
Total Assets 142,255,198 130,938,025
Current Liabilities:    
Accounts payable 8,037,899 13,693,692
License payable 15,650,000 22,650,000
Accrued expenses 25,913,962 4,190,253
Accrued compensation 1,871,320 3,292,447
Note payable 1,000,000
Operating lease liability 176,170 88,348
Total Current Liabilities 51,649,351 44,914,740
Deferred tax liability 7,696,443 7,770,760
Notes payable, net of deferred financing fees 6,410,161  
Operating lease liability – noncurrent 590,787 724,925
Total Liabilities 66,346,742 53,410,425
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 250,000,000 shares authorized; 27,452,570 and 18,067,744 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively 27,452 18,068
Additional paid-in capital 343,704,577 306,336,239
Accumulated deficit (277,118,897) (238,804,129)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 66,613,132 67,550,178
Non-controlling interest 9,295,324 9,977,422
Total Equity 75,908,456 77,527,600
Total Liabilities and Equity $ 142,255,198 $ 130,938,025